Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00270491
Status:
COMPLETED
Last Update Posted:
2011-02-25
First Post:
2005-12-26
Brief Title:
Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer
Sponsor:
ARCAGY GINECO GROUP
Organization:
ARCAGY GINECO GROUP
Study Overview
Official Title:
A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 57 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine in Patients With Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel - capecitabine in patients with metastatic breast cancer
Detailed Description:
The purpose of this study is to know if we can optimize in term of tolerance even of efficacy the plan of administration of weekly paclitaxel associated with capecitabine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None